123 related articles for article (PubMed ID: 32340077)
1. Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B.
Yip TC; Wong VW; Chan HL; Tse YK; Hui VW; Liang LY; Lee HW; Lui GC; Kong AP; Wong GL
J Viral Hepat; 2020 Sep; 27(9):904-914. PubMed ID: 32340077
[TBL] [Abstract][Full Text] [Related]
2. Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus.
Yip TC; Wong GL; Chan HL; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Kong AP; Wong VW
J Gastroenterol Hepatol; 2020 Dec; 35(12):2210-2219. PubMed ID: 32343449
[TBL] [Abstract][Full Text] [Related]
3. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
4. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen.
Cheuk-Fung Yip T; Wai-Sun Wong V; Lik-Yuen Chan H; Tse YK; Pik-Shan Kong A; Long-Yan Lam K; Chung-Yan Lui G; Lai-Hung Wong G
Clin Gastroenterol Hepatol; 2018 May; 16(5):765-773.e2. PubMed ID: 29246694
[TBL] [Abstract][Full Text] [Related]
5. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
Lee CH; Mak LY; Tang EH; Lui DT; Mak JH; Li L; Wu T; Chan WL; Yuen MF; Lam KS; Wong CKH
Hepatology; 2023 Nov; 78(5):1569-1580. PubMed ID: 37055020
[TBL] [Abstract][Full Text] [Related]
6. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis-Related, Child-Pugh A Cirrhosis.
Vilar-Gomez E; Calzadilla-Bertot L; Wong VW; Castellanos M; Aller-de la Fuente R; Eslam M; Wong GL; George J; Romero-Gomez M; Adams LA
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):136-145.e6. PubMed ID: 32389886
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
[TBL] [Abstract][Full Text] [Related]
8. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.
Choi J; Kim GA; Han S; Lim YS
Am J Gastroenterol; 2020 Mar; 115(3):406-414. PubMed ID: 31895708
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
[TBL] [Abstract][Full Text] [Related]
10. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
11. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B.
Lee YB; Ha Y; Chon YE; Kim MN; Lee JH; Park H; Kim KI; Kim SH; Rim KS; Hwang SG
Clin Mol Hepatol; 2019 Mar; 25(1):52-64. PubMed ID: 30360031
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.
Galli A; Ceni E; Mello T; Polvani S; Tarocchi M; Buccoliero F; Lisi F; Cioni L; Ottanelli B; Foresta V; Mastrobuoni G; Moneti G; Pieraccini G; Surrenti C; Milani S
Hepatology; 2010 Aug; 52(2):493-505. PubMed ID: 20683949
[TBL] [Abstract][Full Text] [Related]
13. Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: A population-based cohort study.
Shyu YC; Huang TS; Chien CH; Yeh CT; Lin CL; Chien RN
J Viral Hepat; 2019 Jun; 26(6):718-726. PubMed ID: 30739359
[TBL] [Abstract][Full Text] [Related]
14. The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review.
Huang SC; Kao JH
Kaohsiung J Med Sci; 2024 Jan; 40(1):6-10. PubMed ID: 37732697
[TBL] [Abstract][Full Text] [Related]
15. Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
Kim MN; Han K; Yoo J; Hwang SG; Zhang X; Ahn SH
Int J Cancer; 2023 Oct; 153(8):1448-1458. PubMed ID: 37439276
[TBL] [Abstract][Full Text] [Related]
16. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B.
Hsu YC; Yip TC; Ho HJ; Wong VW; Huang YT; El-Serag HB; Lee TY; Wu MS; Lin JT; Wong GL; Wu CY
J Hepatol; 2018 Aug; 69(2):278-285. PubMed ID: 29551708
[TBL] [Abstract][Full Text] [Related]
17. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
[TBL] [Abstract][Full Text] [Related]
18. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis.
Yip TC; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW; Wong GL
Am J Gastroenterol; 2018 Nov; 113(11):1629-1638. PubMed ID: 30315283
[TBL] [Abstract][Full Text] [Related]
19. The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B.
Chon YE; Jung ES; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Jung KS; Kim SU
J Clin Gastroenterol; 2012 Jul; 46(6):518-25. PubMed ID: 22688146
[TBL] [Abstract][Full Text] [Related]
20. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
